All In Biotech

Drug Trial Radar · NCT03176784

UW Quitting Using Intensive Treatment Study (QUITS)

UW Quitting Using Intensive Treatment Study

Last checked: Nov 19, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,251

Actual

Start

Nov 11, 2017

Primary completion

Jul 9, 2020

Study completion Jul 9, 2020

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jun 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research will determine whether two highly promising modifications to varenicline treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce superior smoking outcomes when they are either used together or alone. Despite their promise, the proposed modifications have never been experimentally evaluated relative to standard varenicline pharmacotherapy. Thus, this innovative research will produce novel evidence regarding how best to help smokers quit, and thereby address the leading cause of preventable mortality and morbidity related to cardiovascular and pulmonary diseases.

Conditions

  • Tobacco Dependence

Interventions

  • VareniclineDrug

    0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

  • Nicotine patchDrug

    14 mg and 7 mg nicotine patches used. See arms for specific durations.

  • Placebo PatchOther

    Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.

  • Placebo PillOther

    Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 52-Week Point-Prevalence AbstinenceTime frame: Assessed 52 weeks after quit date

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UW Center For Tobacco Research and Intervention

    Madison, Wisconsin

  • UW Center for Tobacco Research and Intervention

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.